世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000036266

BRIC諸国(ブラジル、ロシア、インド、中国)のジェネリック医薬品市場の概要、競合分析、および2027年までの予測

MarketLine

BRIC Countries (Brazil, Russia, India, China) Generics Market Summary, Competitive Analysis and Forecast to 2027

発刊日 2023/08/01

言語英語

体裁PDF/131ページ

ライセンス/価格131ページ

0000036266

Single
Site
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

BRIC諸国のジェネリック医薬品の業界プロファイルでは、セクターの規模(2018〜2022 年の価値と量、および 2027 年までの予測)などの主要な定性的および定量的概要情報が提供されます。 プロファイルには、主要な財務指標やセクター内の競争圧力の分析など、主要企業の説明も含まれています。

主なハイライト

  • ブラジル、ロシア連邦、インド、中国(BRIC)は、ジェネリック医薬品業界内で新興かつ急成長している国であり、2022年の市場総額は1,443億3,970万ドルでした。2018〜2022年のCAGRは14.1%で、中国が最も急成長している国となっています。
  • ジェネリック医薬品業界では、中国が BRI 諸国の中で首位に立ち、2022 年の市場収益は 1,116 億 6,690 万ドルとなっています。これにインド、ロシア、ブラジルが続き、それぞれ 176 億 1750 万ドル、119 億 1760 万ドル、31 億 3760 万ドルとなっています。
  • 2027年には中国がBRIC諸国のジェネリック医薬品産業をリードし、その価値は1,711億4,440万ドルになると予想され、インド、ロシア、ブラジルがそれぞれ263億860万ドル、183億2610万ドル、47億3020万ドルと続くと予想されています。

調査範囲

  • BRIC諸国の医薬品市場の規模、成長、主要企業を特定することで、エントリーレベルの調査を実施する時間を節約します。
  • ファイブフォース分析を使用して、競争の激しさを判断し、ひいてはBRIC諸国のジェネリック医薬品市場の魅力を判断します。
  • 主要企業のプロフィールから、ジェネリック医薬品市場の主要企業のBRIC諸国における事業および財務実績の詳細を明らかにします。
  • 金額と量の両方による5年間の予測により、BRIC諸国のジェネリック医薬品市場の将来の成長見通しを理解することで、プレゼンテーションとピッチに重点を置きます。
  • ブラジル、ロシア、インド、中国のデータを比較し、それぞれの国について個別の章を設けています。

調査企業

  • Sanofi SA
  • EMS SA
  • Ache Laboratorios Farmaceuticos SA
  • Eurofarma Laboratorios SA
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Pfizer Inc.
  • Grand Pharmaceutical Group Limited
  • Sun Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Aurobindo Pharma Ltd
  • Cipla Limited
  • Krka, d. d., Novo mesto
  • Abbott Laboratories

レポート詳細

目次

Table of Contents

1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions

2 BRIC Generics
2.1. Industry Outlook

3 Generics in Brazil
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis

4 Macroeconomic Indicators
4.1. Country data

5 Generics in China
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis

6 Macroeconomic Indicators
6.1. Country data

7 Generics in India
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis

8 Macroeconomic Indicators
8.1. Country data

9 Generics in Russia
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis

10 Macroeconomic Indicators
10.1. Country data

11 Company Profiles
11.1. Sanofi SA
11.2. EMS SA
11.3. Ache Laboratorios Farmaceuticos SA
11.4. Eurofarma Laboratorios SA
11.5. Teva Pharmaceutical Industries Limited
11.6. Viatris Inc.
11.7. Pfizer Inc.
11.8. Grand Pharmaceutical Group Limited
11.9. Sun Pharmaceutical Industries Ltd
11.10. Lupin Ltd
11.11. Aurobindo Pharma Ltd
11.12. Cipla Limited
11.13. Krka, d. d., Novo mesto
11.14. Abbott Laboratories

12 Appendix
12.1. Methodology
12.2. About MarketLine

List of Tables
Table 1: BRIC generics industry, revenue($m), 2018-27
Table 2: BRIC generics industry, revenue($m), 2018-22
Table 3: BRIC generics industry, revenue($m), 2022-27
Table 4: Brazil generics market value: $ million, 2017-22
Table 5: Brazil generics market volume: %, 2017-22
Table 6: Brazil generics market geography segmentation: $ million, 2022
Table 7: Brazil generics market value forecast: $ million, 2022-27
Table 8: Brazil generics market volume forecast: %, 2022-27
Table 9: Brazil size of population (million), 2018-22
Table 10: Brazil gdp (constant 2005 prices, $ billion), 2018-22
Table 11: Brazil gdp (current prices, $ billion), 2018-22
Table 12: Brazil inflation, 2018-22
Table 13: Brazil consumer price index (absolute), 2018-22
Table 14: Brazil exchange rate, 2018-22
Table 15: China generics market value: $ million, 2017-22
Table 16: China generics market volume: %, 2017-22
Table 17: China generics market geography segmentation: $ million, 2022
Table 18: China generics market value forecast: $ million, 2022-27
Table 19: China generics market volume forecast: %, 2022-27
Table 20: China size of population (million), 2018-22
Table 21: China gdp (constant 2005 prices, $ billion), 2018-22
Table 22: China gdp (current prices, $ billion), 2018-22
Table 23: China inflation, 2018-22
Table 24: China consumer price index (absolute), 2018-22
Table 25: China exchange rate, 2018-22
Table 26: India generics market value: $ million, 2017-22
Table 27: India generics market volume: %, 2017-22
Table 28: India generics market geography segmentation: $ million, 2022
Table 29: India generics market value forecast: $ million, 2022-27
Table 30: India generics market volume forecast: %, 2022-27
Table 31: India size of population (million), 2018-22
Table 32: India gdp (constant 2005 prices, $ billion), 2018-22
Table 33: India gdp (current prices, $ billion), 2018-22
Table 34: India inflation, 2018-22
Table 35: India consumer price index (absolute), 2018-22
Table 36: India exchange rate, 2018-22
Table 37: Russia generics market value: $ million, 2017-22
Table 38: Russia generics market volume: %, 2017-22
Table 39: Russia generics market geography segmentation: $ million, 2022
Table 40: Russia generics market value forecast: $ million, 2022-27
Table 41: Russia generics market volume forecast: %, 2022-27
Table 42: Russia size of population (million), 2018-22
Table 43: Russia gdp (constant 2005 prices, $ billion), 2018-22
Table 44: Russia gdp (current prices, $ billion), 2018-22
Table 45: Russia inflation, 2018-22
Table 46: Russia consumer price index (absolute), 2018-22
Table 47: Russia exchange rate, 2018-22
Table 48: Sanofi SA: key facts
Table 49: Sanofi SA: Annual Financial Ratios
Table 50: Sanofi SA: Key Employees
Table 51: Sanofi SA: Key Employees Continued
Table 52: EMS SA: key facts
Table 53: EMS SA: Key Employees
Table 54: Ache Laboratorios Farmaceuticos SA: key facts
Table 55: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 56: Eurofarma Laboratorios SA: key facts
Table 57: Eurofarma Laboratorios SA: Key Employees
Table 58: Teva Pharmaceutical Industries Limited: key facts
Table 59: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 60: Teva Pharmaceutical Industries Limited: Key Employees
Table 61: Viatris Inc.: key facts
Table 62: Viatris Inc.: Annual Financial Ratios
Table 63: Viatris Inc.: Key Employees
Table 64: Viatris Inc.: Key Employees Continued
Table 65: Pfizer Inc.: key facts
Table 66: Pfizer Inc.: Annual Financial Ratios
Table 67: Pfizer Inc.: Key Employees
Table 68: Pfizer Inc.: Key Employees Continued
Table 69: Grand Pharmaceutical Group Limited: key facts
Table 70: Grand Pharmaceutical Group Limited: Annual Financial Ratios
Table 71: Grand Pharmaceutical Group Limited: Key Employees
Table 72: Sun Pharmaceutical Industries Ltd: key facts
Table 73: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 74: Sun Pharmaceutical Industries Ltd: Key Employees
Table 75: Lupin Ltd: key facts
Table 76: Lupin Ltd: Annual Financial Ratios
Table 77: Lupin Ltd: Key Employees
Table 78: Aurobindo Pharma Ltd: key facts
Table 79: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 80: Aurobindo Pharma Ltd: Key Employees
Table 81: Cipla Limited: key facts
Table 82: Cipla Limited: Annual Financial Ratios
Table 83: Cipla Limited: Key Employees
Table 84: Krka, d. d., Novo mesto: key facts
Table 85: Krka, d. d., Novo mesto: Annual Financial Ratios
Table 86: Krka, d. d., Novo mesto: Key Employees
Table 87: Krka, d. d., Novo mesto: Key Employees Continued
Table 88: Abbott Laboratories: key facts
Table 89: Abbott Laboratories: Annual Financial Ratios
Table 90: Abbott Laboratories: Key Employees
Table 91: Abbott Laboratories: Key Employees Continued

List of Figures
Figure 1: BRIC generics industry, revenue($m), 2018-27
Figure 2: BRIC generics industry, revenue($m), 2018-22
Figure 3: BRIC generics industry, revenue($m), 2022-27
Figure 4: Brazil generics market value: $ million, 2017-22
Figure 5: Brazil generics market volume: %, 2017-22
Figure 6: Brazil generics market geography segmentation: % share, by value, 2022
Figure 7: Brazil generics market value forecast: $ million, 2022-27
Figure 8: Brazil generics market volume forecast: %, 2022-27
Figure 9: Forces driving competition in the generics market in Brazil, 2022
Figure 10: Drivers of buyer power in the generics market in Brazil, 2022
Figure 11: Drivers of supplier power in the generics market in Brazil, 2022
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2022
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2022
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2022
Figure 15: China generics market value: $ million, 2017-22
Figure 16: China generics market volume: %, 2017-22
Figure 17: China generics market geography segmentation: % share, by value, 2022
Figure 18: China generics market value forecast: $ million, 2022-27
Figure 19: China generics market volume forecast: %, 2022-27
Figure 20: Forces driving competition in the generics market in China, 2022
Figure 21: Drivers of buyer power in the generics market in China, 2022
Figure 22: Drivers of supplier power in the generics market in China, 2022
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2022
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2022
Figure 25: Drivers of degree of rivalry in the generics market in China, 2022
Figure 26: India generics market value: $ million, 2017-22
Figure 27: India generics market volume: %, 2017-22
Figure 28: India generics market geography segmentation: % share, by value, 2022
Figure 29: India generics market value forecast: $ million, 2022-27
Figure 30: India generics market volume forecast: %, 2022-27
Figure 31: Forces driving competition in the generics market in India, 2022
Figure 32: Drivers of buyer power in the generics market in India, 2022
Figure 33: Drivers of supplier power in the generics market in India, 2022
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2022
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2022
Figure 36: Drivers of degree of rivalry in the generics market in India, 2022
Figure 37: Russia generics market value: $ million, 2017-22
Figure 38: Russia generics market volume: %, 2017-22
Figure 39: Russia generics market geography segmentation: % share, by value, 2022
Figure 40: Russia generics market value forecast: $ million, 2022-27
Figure 41: Russia generics market volume forecast: %, 2022-27
Figure 42: Forces driving competition in the generics market in Russia, 2022
Figure 43: Drivers of buyer power in the generics market in Russia, 2022
Figure 44: Drivers of supplier power in the generics market in Russia, 2022
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2022
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2022
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2022

この商品のレポートナンバー

0000036266

TOP